AlphAIAlphAI — Financial news for AI agents
finanznachrichten.de$PMVP

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.

Original reporting
finanznachrichten.de
Published Aug 14, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$PMVP
Bullish
medium confidence
Mentioned
$PMVP
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$PMVPBullishMed
01

Why it matters

Enrollment completion in the registrational Phase 2 monotherapy portion and a planned accelerated-approval NDA submission in Q1 2027 are the main near-term drivers. The cash balance and runway through Q2 2027 frame funding risk.

02

Market read

This is a company-specific biotech update combining clinical milestone progress, a concrete planned NDA timing, and updated liquidity runway.

03

What to watch

The NDA is planned, not filed yet; traders may focus on whether additional cohorts, endpoints, or CMC readiness could delay submission beyond Q1 2027.

Relevance 7/10Novelty 7/10Timing: today, after-hours/next-session biotech catalyst from Q2 results and Q1 2027 NDA plan

Background

PMV Pharma is developing rezatapopt (PC14586), a p53 Y220C-targeted small molecule, in the PYNNACLE Phase 1/2 trial.

Company-level read

Ticker impact

$PMVPBullishMedium confidence
Context

PMV Pharmaceuticals says PYNNACLE Phase 2 monotherapy enrollment is complete and it plans an NDA for rezatapopt in Q1 2027.

Expected impact

Moderate upside bias on renewed biotech risk-on, with volatility tied to NDA readiness and subsequent FDA review milestones.

Evidence & confidence

The article provides concrete development milestones (enrollment completion, planned NDA timing) plus updated cash runway, which can re-rate near-term probability of advancement.

Market effects

Sector

Adds incremental sentiment support for p53 reactivator and precision oncology small-cap development programs, though it is company-specific.

Regional

Limited, primarily US small-cap biotech investor focus.

Global

Low, as the update is tied to US FDA designations and a US NDA timeline.

Counterpoint

What could challenge this read

Cash fell materially from year-end, so the market may discount the NDA timeline if burn rate accelerates or trial execution slips.

Key entities

  • company
    PMV Pharmaceuticals, Inc.

    Nasdaq-listed precision oncology company developing rezatapopt for TP53 Y220C cancers.

  • drug_candidate
    Rezatapopt (PC14586)

    p53 reactivator designed to bind the pocket in TP53 Y220C mutant protein.

  • clinical_program
    PYNNACLE clinical trial

    Phase 1/2 study evaluating rezatapopt in advanced solid tumors with TP53 Y220C mutation.

  • regulator
    FDA

    Granted Fast Track designation and Orphan Drug Designation for rezatapopt in relevant indications.

Read at source← All news

Related articles

$PMVPMed

PMV Pharmaceuticals 3Q 2026: EPS ($0.52) — 10-Q Summary

PMV Pharmaceuticals reported a wider net loss of $34.37M in Q3 2026, with EPS at ($0.52), due to warrant remeasurement loss and offering costs. The company completed enrollment for a Phase 2 trial of rezatapopt and plans to submit an NDA in Q1 2027. Cash reserves totaled $108.5M, expected to last into Q1 2028.

tradingview.com
$PMVPMedAI 8/10

PMV Pharmaceuticals Reports Q3 2026 Results, $108.5M in Cash and Securities

PMV Pharmaceuticals reported a Q3 2026 net loss of $34.4M, with $108.5M in cash. It expects cash to last into Q1 2028. The company completed enrollment for its Phase 2 ovarian cancer trial and plans to submit a rezatapopt NDA in Q1 2027. Research and development expenses were $16.1M, with general and administrative expenses at $4.0M. The company appointed new board members and a chief commercial officer.

tradingview.com
$PMVPMed

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights • Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 • Announced closing of oversubscribed $50 million public offering of sec

SEC EDGAR 8-K
$PMVPMed

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rez

SEC EDGAR 8-K